IXICO PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.125 GBX | -5.80% |
|
-7.14% | -35.00% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.53 times its sales.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -35.00% | 5.19M | - | ||
| +1.77% | 42.75B | B | ||
| +47.70% | 41.61B | A | ||
| +12.24% | 41.34B | B- | ||
| -8.83% | 26.59B | C | ||
| +7.44% | 25.49B | B- | ||
| -23.01% | 18.12B | B | ||
| +30.56% | 12.24B | C+ | ||
| -1.82% | 11.76B | C+ | ||
| +8.35% | 11B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-
- Stock Market
- Equities
- IXI Stock
- Ratings IXICO plc
